Diazyme Laboratories  

12889 Gregg Court
Poway,  CA  92064

United States
  • Booth: 1601

Diazyme is an innovative clinical chemistry reagent manufacturer which develops special chemistry assays for use on conventional open channel automated chemistry platforms. Diazyme introduces emerging cardiovascular biomarkers including lipoprotein-associated phospholipase A2 (Lp-PLA2), Heart-type fatty acid binding protein (hFABP) and Myeloperoxidase (MPO). New diabetes glycemic markers include FDA cleared no pre-treatment enzymatic HbA1c, glycated albumin and 1,5-Anhydroglucitol(1,5-AG). Also available are Kappa and Lambda light chains, procalcitonin(PCT), fibrinogen and adiponectin . Diazyme offers biomarkers for disease and research testing including cardiovascular risk assessment, diabetes, cancer, liver, inflammation, electrolytes, kidney, coagulation and iron status. Diazyme Laboratories is a cGMP and ISO 13485 certified medical device manufacturer.

 Press Releases

  • SAN DIEGO, CA – (August 1, 2016) - Diazyme Laboratories today announced that it has purchased substantially all of the assets of Diadexus, Inc. (Diadexus), including all intellectual property. Diazyme is excited to now offer the Diadexus PLAC® assays.

    "Adding the PLAC assays to Diazyme’s already comprehensive diagnostic testing for heart disease demonstrates Diazyme’s commitment to providing complete clinical diagnostic solutions to doctors and patients” said Dr. Chong Yuan, Managing Director of Diazyme Laboratories. “The PLAC Test ELISA Kit is the only blood test cleared by the FDA to aid in assessing risk for both coronary heart disease (CHD) and ischemic stroke associated with atherosclerosis. The PLAC test for Lp-PLA2 Activity is the only FDA approved test for risk prediction of CHD in patients with no prior history of cardiovascular events. The PLAC assays are recommended to be used as an adjunct to traditional risk factor assessment to identify moderate and high-risk individuals who may actually be at an increased risk for heart attack or stroke.”

    Diazyme Laboratories is a division of General Atomics headquartered in La Jolla, California. Diazyme uses its enzyme and antibody platform technologies to develop innovative assays for clinical and research uses with reduced costs and improved performance. Products include diagnostic blood tests for cardiovascular disease, diabetes, nutritional assessment, liver disease, renal disease and electrolytes. Information regarding Diazyme's enzyme technology and related products can be found on its website at www.diazyme.com.

    For Further Information Contact:

    Dr. Abhijit Datta, Ph.D

    Douglas Borses

    Public Relations
    Craig Silgjord
    (858) 455-3399

 Additional Info

Included in Export Interest Directory?
Business Needs:
Direct Sales


    • AACC Annual Scientific Meeting & Clinical Lab Expo Management
    • SPARGO, Inc.
    • Toll Free (800) 564-4220
    • Phone:  (703) 631-6200
    • Fax (703) 563-2691
    • Email:  aaccexhibits@spargoinc.com